ArticleHepatology (Baltimore, Md.)2020
Ceramides: A Cause of Insulin Resistance in Nonalcoholic Fatty Liver Disease in Both Murine Models and Humans.
Article in Hepatology (Baltimore, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Ceramides in non-communicable diseases: pathways, nutritional modulation, and therapeutic opportunities.Journal of physiology and biochemistry · 2025Review
- Mechanomedicine for Addressing Skeletal Muscle Insulin Resistance.Endocrine reviews · 2025Review
- Nonlinear relationship between body fat percentage and NAFLD mediated by METS-IR: threshold effects and subgroup differences.Scientific reports · 2025Article
- Fatty liver index and risk of type 2 diabetes of adults with normoglycemia: Insights into insulin sensitivity and beta-cell function.PloS one · 2025Article
- Article
- Association between fatty liver index and cardiometabolic multimorbidity: evidence from the cross-sectional national health and nutrition examination survey.Frontiers in cardiovascular medicine · 2024Article
- Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives.Nutrients · 2023Review
- FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.Scientific reports · 2022Article
- Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.World journal of clinical pediatrics · 2022Review
- Ceramide synthase 6 mediates sex-specific metabolic response to dietary folic acid in mice.The Journal of nutritional biochemistry · 2021Article
- Involvement of Ceramides in Non-Alcoholic Fatty Liver Disease (NAFLD) Atherosclerosis (ATS) Development: Mechanisms and Therapeutic Targets.Diagnostics (Basel, Switzerland) · 2021Review
- The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.Nature reviews. Gastroenterology & hepatology · 2021Review
- Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.Molecular metabolism · 2021Review
- Role of ceramides in the pathogenesis of diabetes mellitus and its complications.Journal of diabetes and its complications · 2021Review
- Sphingolipid Profiling: A Promising Tool for Stratifying the Metabolic Syndrome-Associated Risk.Frontiers in cardiovascular medicine · 2021Review
- Dietary Folic Acid Alters Metabolism of Multiple Vitamins in a CerS6- and Sex-Dependent Manner.Frontiers in nutrition · 2021Article
- Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum.Endocrinology, diabetes & metabolism · 2020Review
- Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy.American journal of physiology. Gastrointestinal and liver physiology · 2020Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.